Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
COPINAL 300 mg cápsulas, Placebo has the same composition than imp except the active substance
The George Institute
Chronic liver disease
1 trial -
CORTANCYL 20 mg, comprimé sécable, Placebo of CORTANCYL 20 mg
Pari Pharma GmbH
Adults patients with isolated acute urticaria presenting to the emergency department
1 trial -
CORTANCYL 20 mg, comprimé sécable, placebo of Cortancyl 20 mg, NaCl 0,9% as placebo of kineret, Kineret 100 mg/0.67 ml solution for injection in pre-filled syringe.
Pari Pharma GmbH
Men and women over 18 years of age with renal failure renal failure stages 3b/4/5, renal transplantation or dialysis and an untreated gout attack
1 trial -
COVID-19 Vaccine (Vero cell), Inactivated (Omicron variant)
Sinovac Research and Development Co.,
COVID-19
1 trial -
COVID-19 Vaccine,Inactivated
Sinovac Research and Development Co.,
COVID-19
1 trial -
CPT Dermatophagoides pteronyssinus LETI 100 HEP/ml, Formodual 100/6 microgramos/pulsación Solución para inhalación en envase a presión, Montelukast Teva 10 mg comprimidos recubiertos con película EFG, Budesonida Aldo-Unión- 200 microgramos/pulsación suspensión para inhalación en envase a presión., Salbutamol Aldo-Unión 100 microgramos/dosis suspensión para inhalación en envase a presión, AVAMYS 27.5 micrograms/spray, nasal spray suspension, Formodual Nexthaler 200 microgramos/6 microgramos por inhalación po
Lacuna Pharma Pty Ltd
Allergic rhinoconjunctivitis to Dermatophagoides pteronyssinus and Dermatophagoides farinae
1 trial -
CPX-351
Jazz Pharmaceuticals Ireland Limited
High Risk Acute Myeloid Leukemia
1 trial -
CRT with triple site ventricular stimulation
Rhythm Pharmaceuticals Netherlands B.V.
Heart Failure
1 trial -
CS-3150
Daiichi Sankyo
Hypertension
1 trial -
CSII (Insulin Pump) plus DAFNE
United Therapeutics Europe Ltd
Type 1 Diabetes
1 trial -
CTX001
Vertex Pharmaceuticals (Australia) Pty.
Beta-Thalassemia
1 trial -
CYCLOPHOSPHAMIDE
Pari Pharma GmbH
The study will involve adult women and men from 16 French centers who have hematological malignancies and are candidates for haploidentical HSCT
1 trial -
CYCLOPHOSPHAMIDE, ANTI-HUMAN T-LYMPHOCYTE IMMUNOGLOBULIN FROM RABBITS, RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN, THIOTEPA, FLUDARABINE PHOSPHATE, TREOSULFAN, BLINCYTO 38.5 micrograms powder for concentrate and solution for solution for infusion., BUSULFAN, ETOPOSIDE
The George Institute
Acute Lymphoblastic Leukaemia
1 trial -
CYCLOPHOSPHAMIDE, EPIRUBICIN, TRASTUZUMAB EMTANSINE, PACLITAXEL, DOXORUBICIN, DOCETAXEL, PACLITAXEL ALBUMIN-BOUND, TRASTUZUMAB, CARBOPLATIN, Phesgo 1200 mg/600 mg solution for injection, Phesgo 600 mg/600 mg solution for injection, TRASTUZUMAB, PERTUZUMAB
The George Institute
HER2-positive early breast cancer
1 trial -
CYCLOPHOSPHAMIDE, FLUDARABINE PHOSPHATE, DEXAMETHASONE, DEXAMETHASONE, POMALIDOMIDE, FLUDARABINE PHOSPHATE, DEXAMETHASONE, DEXAMETHASONE, DEXAMETHASONE SODIUM PHOSPHATE, CYCLOPHOSPHAMIDE, POMALIDOMIDE, DEXAMETHASONE, CARFILZOMIB, POMALIDOMIDE, DARATUMUMAB, GPRC5D-TARGETED CAR T, DEXAMETHASONE SODIUM PHOSPHATE, POMALIDOMIDE, TOCILIZUMAB
Celgene Europe Limited
Relapsed or Refractory and Lenalidomide exposed Multiple Myeloma
1 trial -
CYCLOPHOSPHAMIDE, Myocet liposomal 50 mg powder, dispersion and solvent for concentrate for dispersion for infusion., DOXORUBICIN, DOCETAXEL
Ningbo Cancer Hospital
oestrogen-receptor (ER)-positive HER2-negative breast carcinoma
1 trial -
CYCLOPHOSPHAMIDE, PACLITAXEL, MYCOPHENOLATE MOFETIL, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE, CAPECITABINE, EPIRUBICIN, IMFINZI 50 mg/mL concentrate for solution for infusion., CAPECITABINE, CARBOPLATIN, INFLIXIMAB, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL, CYCLOPHOSPHAMIDE, PEMBROLIZUMAB, Datopotamab deruxtecan, Lynparza 150 mg film-coated tablets, Lynparza 100 mg film-coated tablets, MYCOPHENOLATE MOFETIL, DOXORUBICIN
AstraZeneca AB
Triple Negative or Hormone Receptor low/HER2-negative Breast Cancer
1 trial -
CYD Dengue Vaccine
Sanofi Pasteur
Dengue Fever
1 trial -
CYTARABINE, CYTARABINE, Liposomal Annamycin, 0.9% Sodium Chloride Injection, USP/Ph. Eur./BP/JP
Moleculin Biotech
Acute Myeloid Leukemia
1 trial -
Cabozantinib
Takeda
Metastatic Prostate Cancer
1 trial -
Cabozantinib Ipsen 60 mg film-coated tablets, XL092, XL092, XL092, BELZUTIFAN, Cabozantinib Ipsen 20 mg film-coated tablets, XL092
Merck Sharp and Dohme
Renal Cell Carcinoma
1 trial -
Cadisegliatin 800 mg QD
vTv Therapeutics
Diabetes Mellitus, Type 1
1 trial -
Calcium carbonate
Arrowhead Pharmaceuticals Ireland Limited
Uterine Contraction
1 trial -
Canagliflozin
Janssen Cilag International NV
Diabetes Mellitus, Type 2
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources